Indication
Stage III Pancreatic Cancer
52 clinical trials
82 products
28 drugs
Clinical trial
A Phase 1/1b Dose Finding Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Unresectable, Locally Advanced, or Metastatic Non-small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PDAC), and Colorectal Cancer (CRC)Status: Recruiting, Estimated PCD: 2025-06-01
Product
BMF-219Clinical trial
Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage 3 Pancreatic AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
SOCProduct
Modified FOLFIRINOXClinical trial
A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic AdenocarcinomaStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT)Status: Withdrawn, Estimated PCD: 2026-05-31
Drug
AtezolizumabDrug
UTD1Clinical trial
Phase II Clinical Trial Evaluating Intravenous AZD9150 (Antisense STAT3) With MEDI4736 (Anti-PD-L1) in Patients With Advanced Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Clinical trial
Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-03-07
Product
BerzosertibProduct
IrinotecanClinical trial
First-in-Human Phase I Trial of FL118 in Patients With Advanced Pancreatic Ductal AdenocarcinomaStatus: Not yet recruiting, Estimated PCD: 2027-10-01
Product
DDX5 DegraderClinical trial
A Phase I Clinical Trial of CA-4948 in Combination With Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal CarcinomaStatus: , Estimated PCD: 2025-03-15
Product
EmavusertibDrug
GemcitabineDrug
AbraxaneDrug
AN0025Clinical trial
A Phase 1 Study of Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir as Part of a Neoadjuvant Regimen in Patients With Locally Advanced Pancreatic CancerStatus: Completed, Estimated PCD: 2013-08-01
Product
GemcitabineProduct
LeucovorinDrug
fluorouracilProduct
NelfinavirProduct
CobimetinibProduct
VinorelbineProduct
VismodegibDrug
EntrectinibProduct
EribulinProduct
FulvestrantClinical trial
Phase II Study of EUS-Guided Verteporfin PDT in Solid Pancreatic Tumors (VERTPAC-02)Status: Completed, Estimated PCD: 2023-09-20
Product
Photodynamic TherapyProduct
VerteporfinClinical trial
A Pilot Study of Gemcitabine, Abraxane, Metformin and a Standardized Dietary Supplement (DS) in Patients With Unresectable Pancreatic CancerStatus: Active (not recruiting), Estimated PCD: 2020-10-04
Product
PaclitaxelDrug
MetforminClinical trial
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2022-06-22
Product
CediranibProduct
OlaparibClinical trial
A Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid MalignanciesStatus: Completed, Estimated PCD: 2021-10-15
Drug
CisplatinProduct
PalbociclibClinical trial
Phase II Study of Neoadjuvant Intraperitoneal Gemcitabine and Intravenous Gemcitabine With Radiotherapy Followed by Surgery and Adjuvant Intraperitoneal Gemcitabine, Intravenous Gemcitabine, and Fluorouracil in Patients With Advanced Adenocarcinoma of the PancreasStatus: Completed
Product
gemcitabineDrug
DanvatirsenDrug
FOLFOXIRIProduct
LetrozoleProduct
NiraparibDrug
TiragolumabClinical trial
A Phase I, Open-Label, Dose Finding Study of Calaspargase Pegol-Mnkl in Combination With Cobimetinib in Locally-Advanced or Metastatic Pancreatic CancerStatus: Recruiting, Estimated PCD: 2024-12-16
Product
Calaspargase Pegol-mknlClinical trial
A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage ResponseStatus: Recruiting, Estimated PCD: 2024-12-01
Product
TalazoparibClinical trial
BrafPanc: A Phase II Trial of Binimetinib in Combination With Encorafenib in Patients With Pancreatic Malignancies and a Somatic BRAFV600E MutationStatus: Terminated, Estimated PCD: 2023-11-01
Product
PertuzumabDrug
TrastuzumabProduct
BinimetinibProduct
EncorafenibClinical trial
Phase I Pilot Study of Vaccine Therapy With Tumor-Specific Mutated Ras Peptides in the Adjuvant Setting in Patients With Colorectal, Pancreatic, or Lung CancerStatus:
Product
Detox-BClinical trial
A Phase 2A, Dose-Finding Study of Ad5.F35-hGCC-PADRE Vaccine in Adults With Gastrointestinal Adenocarcinomas at Risk of Relapse Post Definitive Surgery and Standard TherapyStatus: , Estimated PCD: 2024-07-01
Clinical trial
Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2025-07-31
Drug
CeralasertibProduct
Trastuzumab EmtansineProduct
DurvalumabProduct
VemurafenibProduct
Ras Peptide Cancer VaccineClinical trial
A Phase 1 Study of Olaparib in Combination With Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic CancerStatus: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
NeoOPTIMIZE: An Open-Label, Phase II Trial to Assess the Efficacy of Adaptive Switching of FOLFIRINOX or Gemcitabine/Nab-Paclitaxel as a Neoadjuvant Strategy for Patients With Resectable and Borderline Resectable/Locally Advanced Unresectable Pancreatic CancerStatus: Recruiting, Estimated PCD: 2025-04-15
Product
CapecitabineDrug
5-FUProduct
Leucovorin CalciumDrug
LosartanDrug
mFOLFOX6Clinical trial
THREAD: A Phase I Trial of Trametinib and Hydroxychloroquine in Patients With Advanced Pancreatic CancerStatus: Recruiting, Estimated PCD: 2025-01-18
Product
HydroxychloroquineProduct
TrametinibClinical trial
A Phase 2 Study of Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine TumorsStatus: Completed, Estimated PCD: 2018-01-01
Product
TMZProduct
AlectinibDrug
AlpelisibClinical trial
A Phase II Study of Neoadjuvant Chemotherapy With and Without Immunotherapy to CA125 (Oregovomab) Followed by Hypofractionated Stereotactic Radiotherapy & Concurrent HIV Protease Inhibitor Nelfinavir in Locally Advanced Pancreatic CancerStatus: Completed, Estimated PCD: 2018-04-01
Product
AnastrozoleDrug
OregovomabClinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIMEStatus: Terminated, Estimated PCD: 2020-12-10
Product
CopanlisibProduct
DarolutamideClinical trial
A Randomized Phase II Study of the Efficacy and Safety of Hypofractionated Stereotactic Radiotherapy and 5FU or Capecitabine With and Without Zometa in Patients With Locally Advanced Pancreatic AdenocarcinomaStatus: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
A Phase I/II Study of Trifluridine/Tipiracil (TAS102) in Combination With Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI CancersStatus: Recruiting, Estimated PCD: 2024-11-28
Clinical trial
A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder CancerStatus: Active (not recruiting), Estimated PCD: 2021-03-02
Clinical trial
Phase Ib Trial of Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal MalignanciesStatus: Completed, Estimated PCD: 2021-06-10
Product
XL888Product
PembrolizumabProduct
AbemaciclibProduct
AbirateroneClinical trial
A Phase 1 Study of Gemcitabine, Nab-Paclitaxel, and Bosentan in Patients With Unresectable Pancreatic CancerStatus: Recruiting, Estimated PCD: 2026-01-27
Product
BosentanClinical trial
Phase I Integrated Biomarker Trial of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Pancreatic and Colorectal CancerStatus: Completed, Estimated PCD: 2021-10-28
Product
VX15/2503Product
IpilimumabDrug
T-VECProduct
GuadecitabineProduct
AfatinibProduct
BicalutamideProduct
BortezomibProduct
CabazitaxelProduct
DabrafenibProduct
DacomitinibProduct
CabozantinibDrug
CelecoxibProduct
Zoledronic AcidProduct
DasatinibDrug
R-CHOPClinical trial
A Phase II Trial of Preoperative FOLFIRINOX Followed by Gemcitabine Based Chemoradiotherapy in Patients With Borderline Resectable Pancreatic AdenocarcinomaStatus: Terminated, Estimated PCD: 2021-11-01
Clinical trial
Weight Loss in Patients With Advanced Stage Pancreatic Cancer: Role of Serotonin and Effects of Telotristat EthylStatus: Active (not recruiting), Estimated PCD: 2023-10-26
Product
Telotristat EthylProduct
EnasidenibProduct
EnzalutamideClinical trial
Phase 1 Trial of Gemcitabine Combined With the Elimusertib (BAY 1895344) ATR Inhibitor With Expansion Cohorts in Advanced Pancreatic and Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Product
ElimusertibClinical trial
BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)Status: Active (not recruiting), Estimated PCD: 2025-02-15
Product
TopotecanClinical trial
A Phase 1/Randomized Phase 2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic AdenocarcinomaStatus: Recruiting, Estimated PCD: 2024-08-01
Product
PeposertibClinical trial
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal MalignanciesStatus: Completed, Estimated PCD: 2017-12-01
Clinical trial
A Phase I Study of SOR-C13 in Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2023-06-20
Clinical trial
Photodynamic Priming to Facilitate Immunologic Activity of Anti-PD1 in Patients With Pancreatic CancerStatus: Not yet recruiting, Estimated PCD: 2029-07-04
Clinical trial
Phase II Open-Label Multi-Cohort Study Evaluating CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Patients With Advanced Chemorefractory Colorectal, Pancreatic, or Other Solid CancersStatus: Recruiting, Estimated PCD: 2028-01-04
Drug
DevimistatClinical trial
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic CarcinomaStatus: Active (not recruiting), Estimated PCD: 2017-09-06
Drug
ErlotinibProduct
VeliparibClinical trial
Phase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary CancerStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Phase Ib/II Treatment of Advanced Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells (BATs) in Combination With Low Dose IL-2 and GM-CSFStatus: Completed, Estimated PCD: 2021-06-21
Drug
IL-2Product
Antibody TherapyDrug
GM-CSFClinical trial
Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and LymphomasStatus: Recruiting, Estimated PCD: 2025-07-01
Product
ZEN-3694Clinical trial
An Open-Label, Phase II Trial to Assess Efficacy and Safety of Onvansertib in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Previously Untreated, Locally-Advanced or Unresectable Pancreatic AdenocarcinomaStatus: Not yet recruiting, Estimated PCD: 2026-05-04
Product
OnvansertibClinical trial
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver DysfunctionStatus: Active (not recruiting), Estimated PCD: 2018-11-29
Product
RomidepsinClinical trial
Immunotherapy for Unresectable Pancreas Cancer: A Phase 1 Study of Intratumoral Recombinant Fowlpox PANVAC (PANVAC-F) Plus Subcutaneous Recombinant Vaccinia PANVAC (PANVAC-V), PANVAC-F and Recombinant Granulocyte-Macrophage Colony Stimulating Factor (rH-GM-CSF)Status: Active (not recruiting), Estimated PCD: 2021-09-02
Product
FalimarevProduct
InalimarevProduct
EntinostatClinical trial
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Product
Anetumab RavtansineDrug
LurbinectedinClinical trial
SHAPER: A Phase 1 Study of Losartan and Hypofractionated Radiation Therapy After Induction Chemotherapy for Borderline Resectable or Locally Advanced Pancreatic CancerStatus: Recruiting, Estimated PCD: 2025-08-08
Clinical trial
A Phase 1b Study of Gemcitabine and Leflunomide in Patients With Unresectable Pancreatic CancerStatus: Recruiting, Estimated PCD: 2026-11-13
Product
CholestyramineProduct
Leflunomide